Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow niche and leukemia.

A D Ho1, W Wagner

  • 1Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. anthony-dick.ho@urz.uni-heidelberg.de

Ernst Schering Foundation Symposium Proceedings
|October 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay.

Immunohematology·2021
Same author

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Bone marrow transplantation·2017
Same author

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.

BMC cancer·2017
Same author

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Oncogenesis·2017
Same author

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Bone marrow transplantation·2017
Same journal

Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Dissecting roles of ubiquitination in the p53 pathway.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Crosstalk between the SUMO and ubiquitin pathways.

Ernst Schering Foundation symposium proceedings·2009
Same journal

The ubiquitin system in health and disease. Preface.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Approaches to discovering drugs that regulate E3 ubiquitin ligases.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Regulation of T cell differentiation and allergic responses by the E3 ubiquitin ligase itch.

Ernst Schering Foundation symposium proceedings·2009
See all related articles

Cancer may arise from malignant transformation of stem cells. Understanding the cellular niche

Area of Science:

  • Stem cell biology
  • Cancer research
  • Hematopoiesis

Background:

  • Evidence suggests cancers originate from malignant stem cell transformation.
  • Acute myeloid leukemia (AML) is driven by a small population of leukemia stem cells (LSCs).
  • Normal hematopoietic stem cells (HSCs) possess self-renewal and differentiation capabilities, maintained by their cellular niche.

Purpose of the Study:

  • To elucidate the role of the cellular niche in maintaining stemness.
  • To understand the interaction between normal HSCs and their niche.
  • To investigate the interaction between LSCs and their niche for improved cancer therapy.

Main Methods:

  • Utilized human hematopoietic stem cells (HSCs) and mesenchymal stromal cells (MSCs) as model systems.

Related Experiment Videos

  • Investigated the critical role of direct cellular niche contact in preserving HSC self-renewal.
  • Examined the niche-dependent self-renewal of leukemia stem cells.

    • Main Results:

    • HSCs differentiate and lose stemness without direct niche interaction.
    • Leukemia stem cells, like normal HSCs, are slow-dividing and rely on the niche for self-renewal.
    • Leukemia stem cells exhibit resistance to conventional chemotherapy due to slow proliferation.

    Conclusions:

    • The cellular niche is crucial for maintaining the stemness of both normal HSCs and LSCs.
    • Understanding HSC-niche and LSC-niche interactions is vital for developing novel therapeutic strategies.
    • Targeting the niche may offer a promising approach to overcome chemotherapy resistance in AML.